Overview

Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess whether abciximab is associated with additional benefit in patients with AMI treated with PCI after high dose clopidogrel loading.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborator:
Technische Universität München
Treatments:
Abciximab
Antibodies, Monoclonal
Calcium heparin
Clopidogrel
Heparin
Immunoglobulin Fab Fragments
Criteria
Inclusion Criteria:

- Patients presenting with ST-Elevation acute myocardial infarction within 24 hours from
the onset of symptoms

Exclusion Criteria:

- Age >80 years

- Malignancies

- Cardiogenic shock

- Prolonged cardio-pulmonary resuscitation

- Increased risk of bleeding

- Relevant hematologic deviations (hemoglobin <100 g/L or hematocrit <34%, platelet
count <100 x 10^9 /L or platelet count >600 x 10^9 /L)

- Known allergy to the study medication

- Pregnancy (present or suspected)